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pneumococcal bacteraemia, pneumococcal pneumonia, otitis media episodes due to pneumococcal infection); long-term disability due to disease; efficacy of the vaccines; and the efficacy of RSV prophylaxis with palivizumab.
Study designs and other criteria for inclusion in the review
The review included cost-effectiveness studies on varicella vaccination, pneumococcal conjugate vaccination and RSV prophylaxis with palivizumab, which were written in English. No further inclusion or exclusion criteria were reported.
Sources searched to identify primary studies
The authors searched MEDLINE for primary studies.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The authors cited 23 studies in total as sources of the effectiveness evidence.
Methods of combining primary studies
It was unclear whether the authors combined the results of the primary studies.
Investigation of differences between primary studies
Results of the review
In the USA, almost 4 million cases of varicella occur each year. The annual hospitalisation rate is 0.0025 and the annual death rate is 0.0000107 among children younger than 15 years of age. Complications due to varicella included bacterial superinfection of skin, lungs and bones, Reye syndrome, pneumonitis, encephalitis, glomerulonephritis, arthritis and death. The mortality rate was found to be higher in infants (6.23 per 100,000) than in children and adolescents aged 1 to 14 years (0.75 per 100,000). The varicella vaccine was found to be 70 to 90% effective against infection, and more than 95% protective against severe for 7 to 10 years.
The incidence of pneumococcal infection was estimated to be 228 per 100,000 in children aged 6 to 11 months, and 87.6 per 100,000 in children under 5 years of age. Complications due to pneumococcal infections in children under 5 years of age included pneumococcal meningitis, pneumococcal bacteraemia and pneumococcal pneumonia. The incidence rates were not reported. The authors reported the results on the efficacy of pneumococcal conjugate vaccination, as derived from two published studies. The results were not combined.
It was found that almost 50% of children were infected with RSV during their first year of life, and almost all children have been infected by the age of 2 years. The highest incidence was found in infants born prematurely, with chronic lung disease, congenital heart disease, multiple congenital anomalies and certain immunodeficiencies.
Measure of benefits used in the economic analysis
The measures of benefits used were: the life-years saved because of each preventive intervention; deaths and cases prevented due to varicella vaccination and due to pneumococcal conjugate vaccination; major sequelae and long-term disability prevented by varicella vaccination; avoided cases of otitis media, pneumonia, bacteraemia and meningitis because of pneumococcal vaccination; and hospitalisations avoided due to RSV prophylaxis with palivizumab.
In general, all of the benefits were discounted at a rate of 5%. The exception was otitis media, pneumonia, bacteraemia and meningitis cases avoided, which were discounted at a rate of 3%.
Direct costs
The health service costs were included. The actual direct medical costs included in the analysis were not described in detail and cost components varied among the three prophylactic strategies. The direct costs were for illness, hospitalisation, emergency department visits, outpatient urgent care visits, advice calls, over-the counter medications, vaccination (dose and administration), and long-term medical care (follow-up care) arising from disability. It was unclear whether the hospitalisation costs included overheads and capital costs. The unit costs and the resource quantities were not reported separately, indeed, the unit costs were not reported. The costs and the quantities of resources used were derived from the literature. All the costs were adjusted to 2002 levels using the medical care component of the Consumer Price Index and were discounted at a rate of 5%.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs included were non-medical costs associated with illness (travel costs, additional childcare), parents' time spent caring for a sick child (parents' work losses), special education costs for neurologically disabled survivors, and future productivity losses due to disability. The cost components varied between the three prophylactic strategies. For varicella and pneumococcal conjugate vaccination, future productivity losses due to a child's premature death were derived from the literature. However, these costs were not available for RSV prophylaxis (palivizumab). The costs and the quantities were not reported separately, indeed, the unit costs were not reported. All the costs were derived from the literature. They were adjusted to 2002 levels using the medical care component of the Consumer Price Index and were discounted at a rate of 5%.
